1f
12
9
1a
8
20
8
49
16
8
19
1
49
2
8
1b
1d
18
89
2a
1d
2 29
1d
25
2a
Wendy Galpern
4dAdjunct Associate Professor of Neurology
7
60
Department: Neurology
4
1
b
1d
46
Contact information
50
4
3
3
3
2
4
b
1f
50
Janssen Research & Development LLC
3d Janssen Pharmaceutical Companies of Johnson & Johnson
3d 1125 Trenton-Harbourton Road
Titusville, NJ 08560
26
3d Janssen Pharmaceutical Companies of Johnson & Johnson
3d 1125 Trenton-Harbourton Road
Titusville, NJ 08560
35
f
13
Education:
21 7 BS 23 (Biology and Psychology) c
29 Tufts University, 1989.
21 c MD, PhD 19 (Neuroscience) c
6e University of Massachusetts Medical School and Graduate School of Biomedical Sciences, 1998.
c
3
3
21
21 7 BS 23 (Biology and Psychology) c
29 Tufts University, 1989.
21 c MD, PhD 19 (Neuroscience) c
6e University of Massachusetts Medical School and Graduate School of Biomedical Sciences, 1998.
c
1f
Post-Graduate Training
24 56 Research Fellow, Harvard Medical School, McLean Hospital, 1997-1998.
24 5d Clinical Fellow in Medicine, Harvard Medical School, Boston, MA, 1998-1999.
24 69 First Year Resident in Medicine, Massachusetts General Hospital, Boston, MA, 1998-1999.
24 5d Clinical Fellow in Neurology, Harvard Medical School, Boston MA, 1999-2003.
24 7c Resident in Neurology, Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA, 1999-2002.
24 80 Clinical and Research Fellow in Movement Disorders, Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA 1b , 2002-2003.
24 5f Postgraduate Trainee, Harvard School of Public Health, Boston, MA, 2003-2003.
24 73 Clinical Fellow in Movement Disorders , Toronto Western Hospital, Toronto, ON, Canada, 2003-2005.
c
3
3
8d
Permanent link24 56 Research Fellow, Harvard Medical School, McLean Hospital, 1997-1998.
24 5d Clinical Fellow in Medicine, Harvard Medical School, Boston, MA, 1998-1999.
24 69 First Year Resident in Medicine, Massachusetts General Hospital, Boston, MA, 1998-1999.
24 5d Clinical Fellow in Neurology, Harvard Medical School, Boston MA, 1999-2003.
24 7c Resident in Neurology, Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA, 1999-2002.
24 80 Clinical and Research Fellow in Movement Disorders, Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA 1b , 2002-2003.
24 5f Postgraduate Trainee, Harvard School of Public Health, Boston, MA, 2003-2003.
24 73 Clinical Fellow in Movement Disorders , Toronto Western Hospital, Toronto, ON, Canada, 2003-2005.
c
2 29
21
1e
1d
24
2b
29
27
23
114 Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, McDonald WM, Marsh L, Rosen AR, Waliczek T, Wright LJ, Galpern WR, Stebbins GT: Development of the comprehensive cervical dystonia rating scale: Methodology 44 Mov Disord Clin Pract 2016 Notes: In Press.
15c Comella CL, Perlmutter JS, Jinnah HA, Factor S, Waliczek TA, Rosen AR, Galpern WR, Goetz CG, Jankovic J, Fox SH, Reich SG, Rodriguez RL, Severt WL, Barbano RL, Adler CH, Stover N, Stebbins G: Reliability of the severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) 57 67th Annual Meeting of the American Academy of Neurology 2015.
d7 Yan L, Hicks M, Winslow K, Comella C, Ludlow C, Jinnah HA, Rosen AR, Wright L, Galpern WR, Perlmutter JS: Secured web-based video repository for multicenter studies 47 Parkinsonism Relat Disord 21(4): 366-71, 2015.
18a Neville J, Kopko S, Odenkirchen J, Galpern W, Marek K, Burn D, Ben Shlomo Y, Grosset DG, Farrer M, Romero K, Aviles E, Dubman S, Gordon M, Roach A, Stephenson D: Impact of therapeutic area specific data standards for Parkinson’s disease. 19th International Congress of Parkinson’s Disease and Movement Disorders 2015.
a7 Galpern, WR : Clinical trials for multiple system atrophy. Lancet Neurol 14(2): 126-27, 2015.
114 Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Chaudhuri KR, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE: Management of impulse control disorders in Parkinson’s disease: Controversies and future approaches 38 Mov Disord 30(2): 150-59, 2015.
10d Cedarbaum JM, Stephenson D, Rudick R, Carrillo M, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Elliott R, Isaac M, Walton M: Commonalities in the development of clinical trial measures in neurology 3f Neurotherapeutics 12(1): 151-69, 2015.
14e Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JLP, Yeatts SD, Jinnah HA: Designing clinical trials for dystonia. Neurotherapeutics 11(1): 117-27, 2014.
151 Comella C, Perlmutter J, Jinnah HA, Adler C, Barbano R, Factor S, Fox S, Goetz C, Galpern W, Jankovic J, Marsh L, McDonald W, Reich S, Rodriguez R, Rosen A, Severt W, Waliczek T, Stebbins G: Clinimetric testing of the modules for the comprehensive cervical dystonia rating scale (CCDRS) 57 66th Annual Meeting of the American Academy of Neurology 2014.
2c
7
1d
1f
Selected Publications
b2 Jinnah HA, Teller JK, Galpern WR: Recent developments in dystonia. Curr Opin Neurol 2016 Notes: In Press.114 Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, McDonald WM, Marsh L, Rosen AR, Waliczek T, Wright LJ, Galpern WR, Stebbins GT: Development of the comprehensive cervical dystonia rating scale: Methodology 44 Mov Disord Clin Pract 2016 Notes: In Press.
15c Comella CL, Perlmutter JS, Jinnah HA, Factor S, Waliczek TA, Rosen AR, Galpern WR, Goetz CG, Jankovic J, Fox SH, Reich SG, Rodriguez RL, Severt WL, Barbano RL, Adler CH, Stover N, Stebbins G: Reliability of the severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) 57 67th Annual Meeting of the American Academy of Neurology 2015.
d7 Yan L, Hicks M, Winslow K, Comella C, Ludlow C, Jinnah HA, Rosen AR, Wright L, Galpern WR, Perlmutter JS: Secured web-based video repository for multicenter studies 47 Parkinsonism Relat Disord 21(4): 366-71, 2015.
18a Neville J, Kopko S, Odenkirchen J, Galpern W, Marek K, Burn D, Ben Shlomo Y, Grosset DG, Farrer M, Romero K, Aviles E, Dubman S, Gordon M, Roach A, Stephenson D: Impact of therapeutic area specific data standards for Parkinson’s disease. 19th International Congress of Parkinson’s Disease and Movement Disorders 2015.
a7 Galpern, WR : Clinical trials for multiple system atrophy. Lancet Neurol 14(2): 126-27, 2015.
114 Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Chaudhuri KR, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE: Management of impulse control disorders in Parkinson’s disease: Controversies and future approaches 38 Mov Disord 30(2): 150-59, 2015.
10d Cedarbaum JM, Stephenson D, Rudick R, Carrillo M, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Elliott R, Isaac M, Walton M: Commonalities in the development of clinical trial measures in neurology 3f Neurotherapeutics 12(1): 151-69, 2015.
14e Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JLP, Yeatts SD, Jinnah HA: Designing clinical trials for dystonia. Neurotherapeutics 11(1): 117-27, 2014.
151 Comella C, Perlmutter J, Jinnah HA, Adler C, Barbano R, Factor S, Fox S, Goetz C, Galpern W, Jankovic J, Marsh L, McDonald W, Reich S, Rodriguez R, Rosen A, Severt W, Waliczek T, Stebbins G: Clinimetric testing of the modules for the comprehensive cervical dystonia rating scale (CCDRS) 57 66th Annual Meeting of the American Academy of Neurology 2014.
2c